Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7–33 (2022).

Article  PubMed  Google Scholar 

Oefelein, M. G., Smith, N. D., Grayhack, J. T., Schaeffer, A. J. & McVary, K. T. Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate. J. Urol. 158, 1460–1465 (1997).

Article  CAS  PubMed  Google Scholar 

Garcia, J. A. & Rini, B. I. Castration-resistant prostate cancer: many treatments, many options, many challenges ahead. Cancer 118, 2583–2593 (2012).

Article  PubMed  Google Scholar 

Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187–1197 (2012).

Article  CAS  PubMed  Google Scholar 

de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).

Article  PubMed  PubMed Central  Google Scholar 

Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502–1512 (2004).

Article  CAS  PubMed  Google Scholar 

de Bono, J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147–1154 (2010).

Article  PubMed  Google Scholar 

de Bono, J. et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 382, 2091–2102 (2020).

Article  PubMed  Google Scholar 

Abida, W. et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J. Clin. Oncol. 38, 3763–3772 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Parker, C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213–223 (2013).

Article  CAS  PubMed  Google Scholar 

Sartor, O. et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091–1103 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marcus, L., Lemery, S. J., Keegan, P. & Pazdur, R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin. Cancer Res. 25, 3753–3758 (2019).

Article  CAS  PubMed  Google Scholar 

Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).

Article  CAS  PubMed  Google Scholar 

Pardoll, D. M. Cancer vaccines. Nat. Med. 4, 525–531 (1998).

Article  CAS  PubMed  Google Scholar 

Euhus, D. M., Gupta, R. K. & Morton, D. L. Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine. Cancer Immunol. Immunother. 29, 247–254 (1989).

Article  CAS  PubMed  Google Scholar 

Simons, J. W. et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59, 5160–5168 (1999).

CAS  PubMed  Google Scholar 

McNeel, D. G. & Disis, M. L. Tumor vaccines for the management of prostate cancer. Arch. Immunol. Ther. Exp. 48, 85–93 (2000).

CAS  Google Scholar 

Meidenbauer, N., Harris, D. T., Spitler, L. E. & Whiteside, T. L. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 43, 88–100 (2000).

Article  CAS  PubMed  Google Scholar 

Perambakam, S. et al. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. Cancer Immunol. Immunother. 55, 1033–1042 (2006).

Article  CAS  PubMed  Google Scholar 

Gulley, J. et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 53, 109–117 (2002).

Article  CAS  PubMed  Google Scholar 

McNeel, D. G. et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J. Clin. Oncol. 27, 4047–4054 (2009).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rausch, S., Schwentner, C., Stenzl, A. & Bedke, J. mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer. Hum. Vaccin. Immunother. 10, 3146–3152 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Freedland, S. J. et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J. Clin. Oncol. 25, 1765–1771 (2007).

Article  PubMed  Google Scholar 

Madan, R. A., Gulley, J. L., Fojo, T. & Dahut, W. L. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 15, 969–975 (2010).

Article  PubMed  PubMed Central  Google Scholar 

Antonarakis, E. S. et al. Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials. Cancer 118, 1533–1542 (2012).

Article  CAS  PubMed  Google Scholar 

Soanes, W. A., Ablin, R. J. & Gonder, M. J. Remission of metastatic lesions following cryosurgery in prostatic cancer: immunologic considerations. J. Urol. 104, 154–159 (1970).

Article  CAS  PubMed  Google Scholar 

Ablin, R. J., Soanes, W. A. & Gonder, M. J. Elution of in vivo bound antiprostatic epithelial antibodies following multiple cryotherapy of carcinoma of prostate. Urology 2, 276–279 (1973).

Article  CAS  PubMed  Google Scholar 

Wolf, P. L., Vazquez, J., Czajkowski, N. P. & Rosenblatt, M. A new method of active immunisation to autologous human tumour tissue. Lancet 2, 905–909 (1967).

PubMed  Google Scholar 

Rothauge, C. F., Kraushaar, J. & Gutschank, S. Specific immunotherapy of prostate carcinoma [German]. Urol. Int. 38, 84–90 (1983).

Article  CAS  PubMed  Google Scholar 

Kreutz, F. T., Schroeder, G. & Berger, M. Long term clinical and biochemical outcomes following immunotherapy with an autologous immunomodulated vaccine in patients with prostate cancer. Cancer Res. 73, Abst 473 (2013).

Article  Google Scholar 

Isaacs, J. T., Isaacs, W. B., Feitz, W. F. & Scheres, J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9, 261–281 (1986).

Article  CAS  PubMed  Google Scholar 

Vieweg, J. et al. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res. 54, 1760–1765 (1994).

CAS  PubMed  Google Scholar 

Dranoff, G. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90, 3539–3543 (1993).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Small, E. J. et al. Granulocyte macrophage colony-stimulating factor–secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res. 13, 3883–3891 (2007).

Article  CAS  PubMed  Google Scholar 

Simons, J. W. & Sacks, N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol. Oncol. 24, 419–424 (2006).

Article  CAS  PubMed  Google Scholar 

Higano, C. S. et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113, 975–984 (2008).

Article  CAS  PubMed  Google Scholar 

Simons, J. W. et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin. Cancer Res. 121, 3394–3401 (2006).

Article  Google Scholar 

Ward, J. E. & McNeel, D. G. GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert. Opin. Biol. Ther. 7, 1893–1902 (2007).

Article  CAS  PubMed  Google Scholar 

Drake, C. G. Immunotherapy for prostate cancer: walk, don’t run. J. Clin. Oncol. 27,